Meldungen zum Thema Medizin

Thema abonnieren
Abonnieren Sie alle Meldungen zum Thema Medizin
Meldungssprache:
Englisch
Inhalte:
Alle
Datum:
Alle
Gestern
Letzte 7 Tage
September
Zurücksetzen
11.09.2018 – 14:31

Merck KGaA

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...
28.08.2018 – 16:39

Thrombosis Research Institute

Real-world Evidence From GARFIELD-AF Shows Superior Reduction in Mortality With Non-vitamin K Antagonists Oral Anticoagulants (NOACs) vs. Vitamin K Antagonists (VKAs) in Newly Diagnosed Atrial Fibrillation

Munich (ots/PRNewswire) - - High-risk patients on anticoagulants (AC) for stroke prevention also have 17% fewer deaths over 2 years of follow-up than patients who are not treated with AC - Patients who receive AC plus add-on antiplatelet therapy (AP) for stroke prevention have a significantly worse prognosis than ...
28.08.2018 – 12:31

Syntellix AG

Syntellix's acquisition of 73% stake in materials specialist MSE results in strategically important vertical integration ahead of intended international flotation

Hannover (ots) - At yesterday's AGM, shareholders of Syntellix AG approved all the management's proposed resolutions by an overwhelming majority of 99%. - Preparations for the intended IPO will be supported by a multinational Supervisory Board comprising internationally renowned personalities from the world of ...
26.08.2018 – 14:00

Novo Nordisk A/S

Ozempic® Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Munich (ots/PRNewswire) - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high ...
06.08.2018 – 09:01

Daiichi Sankyo Europe GmbH

New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA® (edoxaban)

Munich (ots/PRNewswire) - - Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE - This analysis provides benefit/risk assessment in different types of ...
23.07.2018 – 14:12

Anima Biotech

Anima Biotech Announces an Exclusive Collaboration With Lilly for the Discovery and Development of Translation Inhibitors of Several Protein Targets

Bernardsville, New Jersey (ots/PRNewswire) - Anima Biotech today announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform. (Logo: https://mma.prnewswire.com/media/721538/Anima_Biotech_Logo.jpg ...
29.06.2018 – 01:02

Astellas Pharma Europe Limited

Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...